Group 1 - Wanhua Chemical's Yantai Industrial Park's ethylene unit has completed a technical upgrade and resumed production, achieving flexible feedstock switching between ethane and propane, enhancing competitiveness in the petrochemical industry [1] - United Water has won a long-term operation contract for municipal wastewater treatment in Saudi Arabia, with an estimated total investment of approximately 378 million RMB over a 15-year cooperation period [2] - Minsheng Health plans to invest 98 million RMB to establish a fund focused on the health industry, contributing 49% of the total fund size of 200 million RMB [3] Group 2 - Jialitu's shareholder, Anle Group, plans to reduce its stake by up to 3% of the company's total shares [4] - Laiyifen's controlling shareholder intends to reduce its stake by no more than 3% of the total shares [5] - Taifu Pump's actual controller's concerted action party plans to reduce its stake by up to 0.535% [7] Group 3 - Vanke A's executive vice president, Yu Liang, has resigned due to retirement [8] - Tian Sheng New Materials has suspended trading due to a potential change in control involving its largest shareholder [10] - Taisun Wind Power is in the early stages of business layout in the commercial aerospace sector [11] Group 4 - Lushin Investment holds only 0.89% equity in Blue Arrow Aerospace, indicating minimal impact on its financial status [12] - Huibo Pu's controlling shareholder is planning a change in control, leading to stock suspension [13] - Tubaobao's subsidiary is selling a stake in Daziran Home and acquiring specific equity for 4 billion RMB [14] Group 5 - Xingchen Technology plans to repurchase shares worth between 60 million and 120 million RMB for employee stock ownership plans [15] - Pulite expects no large-scale orders for its LCP film products in the brain-computer interface sector in the short term [16] - Rijiu Optoelectronics plans to raise up to 800 million RMB through a private placement for a functional film project [17] Group 6 - Yingqu Technology forecasts a net profit increase of 114.69% to 162.4% in 2025, with expected revenue growth of 13% to 18% [19] - Shanda Electric has won a project from Southern Power Grid worth approximately 13.43 million RMB [20] - Changhong Technology's subsidiary has secured over half of a major semiconductor customer's procurement share, amounting to over 10 million RMB [21] Group 7 - Pairui Co. has signed a framework agreement for bulk procurement of IGBT chips, with projected orders totaling approximately 1.74 billion RMB [22] - Aimeike has received a drug registration certificate for its exclusive distribution of injectable botulinum toxin products in China [23] - Quanyin High-Tech's stock will resume trading after a takeover offer from Zhongzhong Group, which now holds 40.51% of the company [24] Group 8 - Hailiang Co. has decided to suspend its investment in Jinlong Group due to significant external changes [25] - Quanxin Co. plans to issue convertible bonds to raise up to 312 million RMB for aviation communication projects [26] - Kangtai Bio's clinical trial application for a combined vaccine has been accepted by the National Medical Products Administration [27] Group 9 - Huaxia Happiness expects to report a net loss for 2025, with losses projected to exceed the previous year's audited net assets [28] - Xianju Pharmaceutical has received a drug registration certificate for Betamethasone Sodium Phosphate Injection [29] - Huaxia Happiness's controlling shareholder is involved in arbitration with a claim amount of approximately 6.4 billion RMB [30] Group 10 - Shaoneng Co. has launched its smart control center project, with an investment of 8.7 million RMB [31] - Jiangshun Technology is planning to establish an investment fund with professional institutions, with details still under discussion [32] - Beifang Changlong intends to acquire 51% of Shunyi Technology, which may constitute a major asset restructuring [33] Group 11 - Guoji Heavy Industry's revenue from "controlled nuclear fusion" products is currently negligible [34] - Hongrun Construction's shareholder plans to reduce its stake by up to 0.12% [35] - Puni Testing expects a net loss of 200 to 250 million RMB for 2025, although this represents an improvement from the previous year's loss [36] Group 12 - Kede Education's controlling shareholder is planning a change in control through a share transfer agreement [38] - Zhongwei Company’s major shareholder plans to reduce its stake by up to 2% [39] - Tongcheng New Materials is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [40] Group 13 - ST Jianyi's shareholder plans to reduce its stake by up to 1.23% [41]

Investment & Operations - Aimeike's exclusive distribution of botulinum toxin type A injection product has received drug registration certificate [1] - Kangtai Biological's clinical trial application for acellular pertussis-diphtheria-tetanus (component) combined vaccine has been accepted [1] - Runjian Co. signed a strategic cooperation framework agreement with JD Technology to expand in AI applications and intelligent computing cloud [1] - Zhongwu Drone signed a contract for drone systems worth over 100 million, expected to positively impact annual operating performance [1] - Jiechuang Intelligent plans to procure IT equipment and spare parts totaling no more than 4 billion for cloud computing business [1] - Pairui Co. signed a bulk procurement framework agreement for IGBT chips, with forecasted supply total amounting to approximately 131.4 billion for 2028, 2029, and 2030 [1] - Poly United won a bid for a 1.528 billion yuan stripping engineering project [1] - Quanxin Co. plans to issue convertible bonds to raise no more than 312 million for commercial aviation transmission and integrated communication products [1] - Guangdong Power A's Huizhou power plant expansion project (2×1000MW) has commenced operation for unit 5, with a total investment of 8.05 billion [1] - Changhong Technology's subsidiary has secured semiconductor consumables orders from a major domestic wafer factory, expected to account for over half of procurement share by 2026 [1] Performance - Jinli Permanent Magnet expects a net profit increase of 127%-161% year-on-year for 2025, with small batch deliveries of embodied robot motor rotors and magnetic materials [1] - Yingqu Technology anticipates a net profit increase of 114.69%-162.40% year-on-year for 2025 [1] - Absen expects a net profit increase of 105.32%-148.09% year-on-year for 2025 [1] - Industrial Fulian plans to distribute cash dividends totaling 6.55 billion (including tax) for the first half of 2025, with the equity registration date set for January 15, 2026 [1] Capital Operations - Beifang Changlong plans to acquire 51% of Shunyi Technology, expected to constitute a major asset restructuring [2] - Huibo Pu is planning to transfer 25%-30% of its shares, leading to stock suspension [2] - Tiansheng New Materials' largest shareholder Wu Haizhou is planning significant matters that may lead to a change in control, resulting in stock suspension [2] - Quanyin High-Tech's offer from Zhongzhong Group has expired, and the stock will resume trading [2] - Kede Education's actual controller plans to transfer 23.57% of its shares, with Huaxin Future becoming the controlling shareholder [2]

Industry News - China Petroleum and Chemical Corporation (Sinopec) and China National Aviation Fuel Group (CNAF) are undergoing a restructuring process approved by the State Council [5] - The State Administration for Market Regulation has reportedly interviewed six leading photovoltaic companies and industry associations regarding monopoly risks, emphasizing that they must not agree on production capacity, utilization rates, sales volumes, or pricing [5] - The Ministry of Industry and Information Technology, along with three other departments, held a meeting to discuss the competitive order in the power and energy storage battery industry, gathering 16 companies for this purpose [5] - Nestlé has initiated a precautionary recall of specific batches of infant formula in several European countries, with the Chinese subsidiary also complying with the recall requirements [5] Company News - Vanke A announced that Yu Liang has resigned from his positions as director and executive vice president due to retirement [7] - Industrial Fulian announced a cash dividend distribution of 6.55 billion yuan (including tax) for the first half of 2025, with the record date set for January 15, 2026 [8] - Jinli Permanent Magnet has forecasted a net profit increase of 127%-161% year-on-year for 2025, with small batch deliveries of robotic motor rotors and magnetic materials already underway [9] - Puni Testing announced significant stock trading fluctuations, expecting a loss of 200 million to 250 million yuan for the 2025 fiscal year [10] - Changhong Technology reported that its subsidiary has secured over half of the procurement share from a major domestic wafer factory for semiconductor consumables [10] - Pairui Co. signed a framework agreement for bulk procurement of IGBT chips, with a projected total supply amount of approximately 1.3 to 1.4 billion yuan for the years 2028, 2029, and 2030 [11] - Allxin Co. plans to issue convertible bonds to raise no more than 312 million yuan for the production of integrated communication products for commercial aviation [11] - Tian Sheng New Materials announced that its largest shareholder is planning a significant matter that may lead to a change in control, resulting in a stock suspension [12] - Aimei Ke announced that its exclusively distributed injectable botulinum toxin product has received drug registration certification [12] - Guangdong Electric Power A reported that the expansion project for units 5 and 6 at the Huilai Power Plant has been completed, with a total investment of 8.05 billion yuan [12]

智通财经1月8日讯（记者 何凡）今日国内第七款注射用 A 型肉毒毒素产品获批上市，该A型肉毒毒素 100U产品由爱美客（300896.SZ）从韩国Huons BP引入。随着越来越多的玩家进入肉毒毒素赛道，爱美 客能否依靠上述产品缓解业绩下滑态势值得持续关注。 爱美客方面表示，本次注射用 A 型肉毒毒素产品药品注册证的获取是公司战略布局的关键里程碑，该 产品通过与现有产品的组合，能为客户提供更全面的综合解决方案，有利于增强公司的核心竞争力。 面对每天上千份上市公司公告该看哪些？重大事项公告动辄几十页几百页重点是啥？公告里 一堆专业术语不知道算利好还是利空？请看智通财经公司新闻部《速读公告》栏目，我们派 驻全国的记者们将于公告当晚为您带来准确、快速、专业的解读。 今日晚间，爱美客公告称，公司在中国（包括澳门和香港）独家经销韩国Huons BP生产的注射用A型肉 毒毒素产品获得国家药监局核准签发的《药品注册证书》。 2022年5月20日，爱美客与Huons BP签订《经销协议》，公司以研发注册方式引进 Huons BP 生产的注 射用 A 型肉毒毒素产品，并在约定经销区域（指中国，包括澳门和香港）内作为 Huons ...

爱美客（300896）(300896.SZ)公告，公司在中国独家经销韩国Huons BP生产的注射用A型肉毒毒素产品 获得国家药品监督管理局核准签发的《药品注册证书》。 ...

（文章来源：证券日报） 证券日报网讯 1月8日，爱美客发布公告称，2026年1月8日，公司在中国（含港澳）独家经销韩国 HuonsBioPharmaCo.，Ltd.生产的注射用A型肉毒毒素获国家药监局核准签发药品注册证书，规格100U/ 瓶，批准文号国药准字SJ20260001，有效期至2031年1月4日。 ...

根据公告，2022年5月20日，爱美客与Huons BP签订《经销协议》，以研发注册方式引进Huons BP生产 的注射用A型肉毒毒素产品，并在约定经销区域（中国）内作为Huons BP指定的唯一且排他的进口商、 经销商。 北京商报讯（记者 王寅浩 宋雨盈）1月8日，爱美客发布公告称，公司在中国独家经销韩国Huons BioPharma Co., Ltd.（以下简称"Huons BP"）生产的注射用A型肉毒毒素产品获得国家药品监督管理局核 准签发的《药品注册证书》。 ...

格隆汇1月8日丨爱美客(300896.SZ)公布，公司在中国（包括澳门和香港）独家经销韩国 Huons BioPharma Co., Ltd.（简称"Huons BP"）生产的注射用 A 型肉毒毒素产品获得国家药品监督管理局核准 签发的《药品注册证书》。公司独家经销的注射用A型肉毒毒素产品药品注册证的获取是公司战略布局 的关键里程碑，该产品通过与现有产品的组合，能为客户提供更全面的综合解决方案，有利于增强公司 的核心竞争力。 ...

Group 1 - Runjian Co., Ltd. signed a strategic cooperation framework agreement with JD Technology to collaborate in AI applications, intelligent computing cloud expansion, and AIDC cooperation [1] - The partnership aims to commercialize AI technology in various sectors including smart agriculture, intelligent parks, digital cultural tourism, and smart retail [1] - Both companies will enhance the "Runjian Cloud" and leverage JD's extensive market channels for business expansion [1] Group 2 - Vanke A announced that Yu Liang will retire due to age, effective January 8, 2026, and will no longer hold any position in the company [2] - The resignation will not affect the board's operation or the company's daily business [2] Group 3 - Zhong Wuyun signed a contract exceeding 100 million yuan for a drone system, which is over 50% of the company's audited revenue from the last fiscal year [3] - The contract is expected to positively impact the company's operating performance for the contract execution year [3] Group 4 - Changhong Technology's subsidiary secured over half of a major domestic wafer factory's procurement share for semiconductor consumables, amounting to over 10 million yuan [4] - This order is expected to enhance the company's market expansion in semiconductor consumables and strengthen its competitive advantage [4] Group 5 - Huibo Pu is planning to transfer 25%-30% of its shares, which may lead to a change in the controlling shareholder [5] - The stock will be suspended from trading starting January 9, 2026, for up to two trading days [5] Group 6 - Tiansheng New Materials announced that its largest shareholder is planning a significant matter that may lead to a change in control [6] - The stock will be suspended from trading starting January 9, 2026, for up to two trading days [6] Group 7 - Hu Silicon Industry reported that the National Integrated Circuit Industry Investment Fund reduced its stake by 0.2%, from 17.16% to 16.96% [9] Group 8 - Guangdong Yuedian A announced that the 5th unit of the Huizhou Power Plant expansion project has been put into operation, with a total investment of 8.05 billion yuan [10] - The project is expected to generate an annual power output of 8.84 billion kWh, which is significant for expanding the company's power generation capacity [10] Group 9 - Tianneng Co., Ltd. plans to use up to 12 billion yuan of idle funds for entrusted wealth management, focusing on low to medium-risk financial products [11] Group 10 - Quanxin Co., Ltd. plans to issue convertible bonds to raise up to 312 million yuan for commercial aviation transmission and communication integration projects [12] Group 11 - Meike Home announced a significant loss and decided to suspend operations at its Tianjin manufacturing facilities due to low utilization rates [13] - The company aims to optimize idle capacity and reduce losses while ensuring employee rights during the transition [13] Group 12 - Aimeike announced that its exclusive distributor for botulinum toxin products received a drug registration certificate, marking a key milestone in its strategic layout [14] Group 13 - Pairui Co., Ltd. signed a framework agreement for bulk procurement of IGBT chips, with projected supply amounts totaling approximately 1.3 to 1.4 billion yuan for 2028-2030 [15]

智通财经APP讯，爱美客(300896.SZ)公告，公司在中国独家经销韩国Huons BP生产的注射用A型肉毒毒 素产品获得国家药品监督管理局核准签发的《药品注册证书》。 ...